FAMENITY CO., LTD. – Trademark Portfolio
Entity Type: 03
FAMENITY CO., LTD. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 17 trademarks are registered and 2 are pending. Notable registered marks include BF-7, COGUP, MR-10, MS-10, and CEREUP. The owner is based in Gwacheon.
1104Ho,2,Byeoryangsangga-ro, Gyeonggi-do
Gwacheon 13837 , KR
Showing of trademarks Trademarks
Trademark Classifications
FAMENITY CO., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does FAMENITY CO., LTD. have?
FAMENITY CO., LTD. has 19 U.S. trademarks filed with the USPTO. Of these, 17 registered, 2 pending.
What trademark classes does FAMENITY CO., LTD. file in?
FAMENITY CO., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are FAMENITY CO., LTD.'s most well-known trademarks?
FAMENITY CO., LTD.'s registered trademark portfolio includes well-known marks such as BF-7, COGUP, MR-10, MS-10, and CEREUP. These are among 17 currently registered trademarks in the portfolio.
What is FAMENITY CO., LTD.'s trademark registration success rate?
FAMENITY CO., LTD. has a 100% trademark registration rate, with 17 out of 17 resolved applications resulting in successful registration. Currently, 2 applications are pending review.